StaR technology
E474947
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
All labels observed (1)
| Label | Occurrences |
|---|---|
| StaR technology canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850498 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: StaR technology Context triple: [Heptares Therapeutics, technologyBrand, StaR technology]
-
A.
Efficeon
Efficeon is a family of low-power, x86-compatible microprocessors developed by Transmeta as the successor to its Crusoe line, aimed primarily at mobile and embedded computing devices.
-
B.
Phystech System
Phystech System is a rigorous, research-oriented educational model used at the Moscow Institute of Physics and Technology that tightly integrates students into leading scientific laboratories and real-world research from early in their studies.
-
C.
GoldStar
GoldStar was the original brand name of the South Korean electronics company now known as LG Electronics, under which it produced a wide range of consumer electronics and home appliances.
-
D.
NISTAR
NISTAR is a radiometer aboard the Deep Space Climate Observatory that measures Earth’s reflected and emitted radiation to study the planet’s energy budget and climate.
-
E.
TriStar C2
The TriStar C2 is a Royal Air Force variant of the Lockheed L-1011 TriStar airliner adapted for military transport and support roles.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: StaR technology Target entity description: StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
-
A.
Efficeon
Efficeon is a family of low-power, x86-compatible microprocessors developed by Transmeta as the successor to its Crusoe line, aimed primarily at mobile and embedded computing devices.
-
B.
Phystech System
Phystech System is a rigorous, research-oriented educational model used at the Moscow Institute of Physics and Technology that tightly integrates students into leading scientific laboratories and real-world research from early in their studies.
-
C.
GoldStar
GoldStar was the original brand name of the South Korean electronics company now known as LG Electronics, under which it produced a wide range of consumer electronics and home appliances.
-
D.
NISTAR
NISTAR is a radiometer aboard the Deep Space Climate Observatory that measures Earth’s reflected and emitted radiation to study the planet’s energy budget and climate.
-
E.
TriStar C2
The TriStar C2 is a Royal Air Force variant of the Lockheed L-1011 TriStar airliner adapted for military transport and support roles.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
drug discovery platform
ⓘ
proprietary technology ⓘ protein stabilization technology ⓘ |
| appliesTo | G protein–coupled receptors NERFINISHED ⓘ |
| associatedWith | Sosei Group Corporation NERFINISHED ⓘ |
| basedOn |
protein engineering
ⓘ
thermostabilizing point mutations ⓘ |
| developer | Heptares Therapeutics NERFINISHED ⓘ |
| enables |
biophysical characterization of GPCR–ligand interactions
ⓘ
crystallization of GPCRs ⓘ high-resolution GPCR structures ⓘ screening of small molecules against stabilized GPCRs ⓘ |
| field |
G protein–coupled receptor research
ⓘ
structure-based drug discovery ⓘ |
| fullName | Stabilized Receptor technology NERFINISHED ⓘ |
| goal | to enable drug discovery against previously intractable GPCR targets ⓘ |
| hasCommercialUse |
biotechnology research collaborations
ⓘ
pharmaceutical research ⓘ |
| improves |
stability of GPCRs in detergent solutions
ⓘ
suitability of GPCRs for X-ray crystallography ⓘ suitability of GPCRs for biophysical assays ⓘ |
| intellectualPropertyStatus | patented technology ⓘ |
| owner | Heptares Therapeutics NERFINISHED ⓘ |
| purpose |
enabling detailed structural analysis of GPCRs
ⓘ
enabling structure-based design of ligands ⓘ facilitating fragment-based drug discovery on GPCRs ⓘ stabilization of GPCRs ⓘ |
| relatedTo |
GPCR structural biology
ⓘ
membrane protein crystallography ⓘ structure-based medicinal chemistry ⓘ |
| shortName | StaR NERFINISHED ⓘ |
| supports |
fragment screening on GPCR targets
ⓘ
rational design of GPCR ligands ⓘ structure-based virtual screening ⓘ |
| targetType |
class A GPCRs
ⓘ
class B GPCRs ⓘ class C GPCRs ⓘ membrane proteins ⓘ |
| technologyType |
enabling technology
ⓘ
platform technology ⓘ |
| usedBy | Heptares Therapeutics drug discovery programs ⓘ |
| usedFor |
identification of GPCR agonists
ⓘ
identification of GPCR allosteric modulators ⓘ identification of GPCR antagonists ⓘ lead optimization of GPCR-targeted compounds ⓘ |
| usedIn |
early-stage drug discovery
ⓘ
lead identification ⓘ lead optimization ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: StaR technology Description of subject: StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.